Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
Go back to Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies| NOVEN PHARMACEUTIC (NASDAQ: NOVN) | Delayed: 0.09 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.09 | 52 Week High | $23.79 | |||
| Open | $10.12 | 52 Week Low | $13.73 | |||
| Day High | $0.09 | P/E | 0.09 | |||
| Day Low | $0.09 | EPS | $1.05 | |||
| Volume | 1,574,031 | |||||
| NOVARTIS AG (NYSE: NVS) | Delayed: 140.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $140.98 | 52 Week High | $89.15 | |||
| Open | $140.98 | 52 Week Low | $69.84 | |||
| Day High | $140.98 | P/E | N/A | |||
| Day Low | $140.98 | EPS | $0.00 | |||
| Volume | 43,749 | |||||
